1. Pink Sheet
  2. >>Pathways & Standards
  3. >>User Fees

GDUFA III Talks Completed; Fees will Fund Inspection, Complex Generic Improvements

 
• By Derrick Gingery

Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.

Agreement reached
GDUFA III was the last of three FDA human drug and biologic user fee renewal agreements to be completed. • Source: Alamy

US Food and Drug Administration and industry representatives have reached an agreement to extend the generic drug user fee program another five years, which will include enhanced communications on inspections, as well as additional clarity on so-called “imminent” ANDA approvals.

FDA confirmed on 2 September that the GDUFA III talks have been completed and the ratification process among the various...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from User Fees

More from Pathways & Standards

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which led to missed guidance publication deadlines.

Nipah Vaccine With ‘Pandemic Potential’ Wins EMA PRIME Designation

 
• By Neena Brizmohun

The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.

Elegy For SACHRP: US HHS Research Protection Panel Tackled Tough Pediatric Trial Questions

 
• By Bridget Silverman

The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.